Article type: Progress Update
Market cap: <$50m
Exchange: AIM
Avg daily trading volume: 1.5m-2m shares
Disclosure and disclaimer:
As of August 1st, 2026, I own shares of the company discussed in this article and may benefit if their price rises. I hold no other securities or derivatives of the company.
Neither I nor PaedIT UG (haftungsbeschränkt) received compensation or other consideration from the company or anyone acting on its behalf. Neither I nor PaedIT UG has a consulting, promotional, investor-relations or advisory relationship with the company. The company did not review this article.
This article reflects information available at publication and contains my assumptions, estimates, valuations and opinions, which may be incomplete or wrong. Any valuation is an estimate, not a forecast or guarantee. I may trade the securities discussed after publication without notice, and I do not undertake to update the article.
This is general research for a broad audience, not personalised investment, financial, legal or tax advice, or an offer or solicitation to transact. It does not consider any reader’s circumstances. Readers must conduct independent due diligence. Securities can be volatile and illiquid, and investing may result in partial or total loss of capital.
I use AI tools to assist with research, drafting, and editing, but I review the work and remain responsible for the published content.
Introduction
Since my very recent article, the company issued three updates that I wanted to capture in an article instead of a Substack Chat thread. For reference and context, my last article was
